Niagen Bioscience’s (NAGE) Buy Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group reiterated their buy rating on shares of Niagen Bioscience (NASDAQ:NAGE) in a research report sent to investors on Tuesday,Benzinga reports. Canaccord Genuity Group currently has a $13.00 price target on the stock.

NAGE has been the topic of several other reports. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research note on Thursday, January 22nd. Wall Street Zen upgraded Niagen Bioscience from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.00.

Niagen Bioscience Trading Down 3.1%

NASDAQ NAGE opened at $4.38 on Tuesday. The firm’s fifty day simple moving average is $5.08 and its two-hundred day simple moving average is $6.47. The firm has a market capitalization of $350.75 million, a P/E ratio of 21.90 and a beta of 2.23. Niagen Bioscience has a 12-month low of $4.16 and a 12-month high of $14.69.

Institutional Investors Weigh In On Niagen Bioscience

A number of large investors have recently made changes to their positions in NAGE. Financial Consulate Inc. acquired a new position in shares of Niagen Bioscience in the 3rd quarter valued at $33,000. New York State Teachers Retirement System acquired a new stake in Niagen Bioscience during the 4th quarter worth about $30,000. Ameritas Investment Partners Inc. acquired a new stake in Niagen Bioscience during the 3rd quarter worth about $45,000. State of Alaska Department of Revenue purchased a new stake in Niagen Bioscience during the 3rd quarter valued at about $44,000. Finally, North Star Investment Management Corp. purchased a new stake in Niagen Bioscience during the 3rd quarter valued at about $47,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.